Drugs / IBI939
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04672369 | Jun 2021 → Jan 2023 | lung cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04672356 | Jan 2021 → Jan 2023 | lung cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04353830 | May 2020 → May 2022 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04672356 ↗ |
| Known as | Tamgiblimab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650473 ↗ |
| Action | Inhibit | “anti-TIGIT antibody” NCT04672369 ↗ |
| Modality | Protein / enzyme biologic | “recombinant fully human anti-TIGIT antibody (IBI939)” NCT04672369 ↗ |
| Route | Intravenous | “IBI939 will be given via intravenous (IV) infusion” NCT04353830 ↗ |
| Target | TIGIT | “anti-TIGIT antibody” NCT04672356 ↗ |